Study Overview: This research aims to find the best dose of a new drug called BGB-16673 for people with certain blood cancers. The study has two parts: Phase 1 to test different doses and Phase 2 to check how well the chosen dose works.
Eligibility: To join, participants must have one of these cancers: Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), or others like them. They should have tried similar treatments before but have not responded well. Participants must be physically able, as per the Eastern Cooperative Oncology Group (ECOG) Performance Status, which is a scale from 0 (fully active) to 2 (capable of self-care but unable to work). People with other active cancers or health issues affecting the brain or nervous system cannot participate.
- Length: Study is divided into two phases, exact duration per phase not specified.
- Visits: Participants may need to visit the clinic several times for assessments and monitoring.
- Risks: Possible side effects as with any cancer treatment; specific risks will be discussed with you.